An Insider at Hims & Hers Just Filed. Here's What It Says About Buying the Dip

Hims & Hers' Chief Legal Officer Soleil Boughton sold 21,500 shares (~$605,000) on August 14 through a non-discretionary tax withholding transaction, retaining 339,075 shares. The sale does not reflect a shift in the insider's assessment of the company. Despite the stock's -40% one-year return, the underlying business shows strength with 38% revenue growth to $753.2 million last quarter and raised full-year guidance to $3.1-$3.3 billion. However, an FTC lawsuit over data sharing and billing practices creates uncertainty, with a $47.5 million legal contingency already impacting earnings.

08/19/2026, 5:29 AM • The Motley Fool

What Long-Term Investors Should Know About This Hims Insider Filing

Hims & Hers Chief Operating Officer Michael Chi sold 47,702 shares worth $1.3 million on August 14, but this was a non-discretionary tax withholding tied to quarterly RSU vesting, not an active investment decision. Chi retains 470,687 shares and has nearly 600,000 RSUs vesting through June 2029, indicating confidence in the company's future. The sale reflects Chi's focus on managing the company's aggressive expansion, including the major Eucalyptus acquisition and international growth targeting $600 million in 2026 revenue.

08/19/2026, 5:21 AM • The Motley Fool

A Hims & Hers Insider Disposed of Stock as the Company Pushes Into Testosterone and Peptides. Here's What to Know

Chief Medical Officer Patrick Harrison Carroll sold 10,201 shares of Hims & Hers Health (HIMS) worth $287,158 on August 14 due to routine tax withholding obligations from RSU vesting. The sale is non-discretionary and does not reflect insider sentiment. The company is expanding into new specialties like testosterone replacement therapy, which is approaching $100 million in annual run rate, though this expansion may compress gross margins.

08/19/2026, 5:11 AM • The Motley Fool

HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm

The Federal Trade Commission filed a lawsuit against Hims & Hers Health, Inc. on July 29, 2026, alleging the company engaged in deceptive privacy practices by sharing customers' sensitive medical information with third-party advertisers including Meta Platforms and Snap. Following the lawsuit announcement, HIMS stock price fell over 14%. A securities litigation law firm is investigating potential federal securities law violations on behalf of affected investors.

08/09/2026, 5:22 PM • GlobeNewswire

HIMS & HERS HEALTH, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Law firm Kirby McInerney LLP is investigating Hims & Hers Health following an FTC lawsuit alleging the company engaged in deceptive privacy practices by sharing customers' sensitive medical information with third-party advertisers including Meta Platforms. The announcement triggered a 14.73% stock price decline on July 29, 2026.

08/05/2026, 8:00 PM • GlobeNewswire

Lowey Dannenberg, P.C. Investigates Hims & Hers Health, Inc. for Alleged Tracking of User Data

Lowey Dannenberg, P.C. announces an investigation into Hims & Hers Health, Inc. for allegedly collecting and sharing subscribers' sensitive health information with third parties without proper consent, in violation of privacy policies and federal/state privacy laws. Eligible U.S. residents may recover up to $10,000 in compensation through binding mass arbitration.

07/15/2026, 2:44 PM • GlobeNewswire

Hims & Hers Pullback Could Create a Better Entry Into GLP-1 Demand

Hims & Hers (HIMS) has surged 45% in the past month and 160% year-to-date, but technical indicators suggest a correction is due. However, a major catalyst looms: employers are planning to drop GLP-1 drug coverage in 2027, which should drive patients to direct-to-consumer telehealth providers like Hims & Hers. The stock's RSI is overbought at 70.86, and Wall Street remains bearish with only 4 of 16 analysts rating it a Buy, suggesting a pullback could present a better entry point for long-term investors.

07/07/2026, 11:37 AM • Investing

Is Hims & Hers Stock an Undervalued Stock to Buy?

The article examines whether Hims & Hers Health (HIMS) represents an undervalued investment opportunity. The stock is noted as one of the most volatile in the market, with recent price movements following earnings announcements. The article suggests the healthcare industry is ripe for disruption, positioning the company within this context.

06/01/2026, 9:08 PM • The Motley Fool

Hims & Hers Debt-Funded Expansion Tests Its Global Telehealth Ambitions

Hims & Hers is pursuing aggressive international expansion through its $1.15 billion acquisition of Australian telehealth platform Eucalyptus, funded by $350 million in zero-coupon convertible debt. However, the company faces headwinds following a significant earnings miss in May, with shares down 18% since the earnings call and one-year performance down over 50%. While the acquisition could diversify revenue away from U.S. regulatory risks, concerns remain about the company's slowing growth trajectory and high short interest of 31.4%.

05/28/2026, 11:44 AM • Investing

Hims & Hers Massive Stock Drop Explained

Hims & Hers announced a $350 million convertible debt offering to fund growth plans. The debt will either be converted to stock, diluting shareholders, or require cash repayment, adding significant risk to the business. The company has limited time to prove it remains a growth company to the market.

05/19/2026, 2:06 PM • The Motley Fool

Hims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign?

Hims & Hers reported strong Q1 2026 revenue growth of 4% year-over-year to $608.1 million and raised full-year guidance to $2.8-3.0 billion. However, the company swung to a $92.1 million net loss from $49.5 million profit a year earlier, with adjusted EBITDA falling sharply and gross margins compressing from 73% to 65%. The shift from high-margin compounded GLP-1 drugs to lower-margin branded weight-loss products, combined with increased spending on international expansion, AI, and diagnostics, triggered a 12% stock decline despite revenue growth.

05/15/2026, 5:05 AM • The Motley Fool

Is Hims and Hers Health Stock a Buy After Its Latest Dip?

Hims & Hers Health raised its 2026 revenue forecast to $2.8-3.0 billion but significantly lowered adjusted EBITDA guidance to $275-350 million due to margin compression from its pivot to branded weight-loss drugs like Wegovy. Q1 results showed 4% revenue growth but a 51% drop in adjusted EBITDA and a loss per share. The analyst views the stock as speculative, with potential upside only if the FDA lifts its ban on peptides.

05/14/2026, 12:30 PM • The Motley Fool

S&P 500 Valuation Looks Stretched as Inflation Reprices Rate-Cut Odds

Hot inflation data (April PPI up 1.4% vs 0.5% consensus) has forced markets to reprice lower rate-cut expectations, pressuring equities and extending Treasury yields to 4.475%. While semiconductor stocks rallied on Trump's Beijing summit and memory pricing strength, the broader market faces stretched valuations with asymmetric earnings reaction patterns favoring misses over beats. Kevin Warsh is set to become Fed chair amid the worst macro moment for establishing credibility.

05/13/2026, 12:22 PM • Investing

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recov

Hims & Hers Health stock fell over 12% after reporting Q1 FY2026 earnings and revenue misses, marking its fourth miss in five quarters. Despite disappointing results, the company highlighted strong traction from its GLP-1 partnership with Novo Nordisk, fulfilling over 125,000 Wegovy shipments and raising full-year guidance. The company operates in high-growth markets including telehealth, weight loss, and hair thinning, with long-term analyst sentiment remaining mostly positive despite near-term volatility.

05/12/2026, 1:49 PM • Investing

Why Hims & Hers Health Stock Just Crashed

Hims & Hers Health stock tumbled 12% after missing Q1 earnings expectations with a $0.40 loss per share versus forecasted $0.01 profit, and revenue of $608M versus expected $616.5M. Despite the miss, the company raised full-year sales guidance to $2.8-3B and projects $6.5B in 2030 sales, citing expansion into new markets and drug categories while shifting GLP-1 focus to reselling branded products from major manufacturers.

05/12/2026, 11:32 AM • The Motley Fool